San Juan RA,Gómez TE, Pérez RJ, Setién RRA

Language: Spanish
References: 24
Page: 287-291
PDF size: 724.80 Kb.

ABSTRACT

Primary cutaneous anaplastic large cell lymphoma (PCALCL) along with lymphomatoid papulosis constitute the CD30+ lymphoproliferative syndromes. These represent the second most frequent group of cutaneous T-cell lymphomas after mycosis fungoides. Differentiation between PCALCL and other proliferations of lymphocytes that can present CD30+ cells, as well as its systemic counterpart of lymph node origin, is the key in obtaining a precise diagnosis. Clinically it affects the elderly, ocurring as a cutaneous nodule with tendency to ulceration. It is currently considered a low-grade lymphoma, with a good prognosis and an adequate response to treatments such as local radiation, surgery or chemotherapy. The prevalence of cutaneous T-cell lymphoma has been consistently increasing. We present the case of a 74-year-old male with an ulcerated tumor located in the right forearm. The histological and immunohistochemical study confirmed PCALCL.

REFERENCES

1. Calzado Villarreal L, Polo Rodríguez I y Ortiz Romero P, Primary cutaneous cd30+ lymphoproliferative disorders, Actas Dermo-Sifiliográficas 2009; 101(2):119-28.

2. Willemze R y Meijer C, Primary cutaneous cd30-positive lymphoproliferative disorders, Hematol Oncol Clin North Am 2003; 17(6):1319-32.

3. Le Boit PE, Lymphomatoid papulosis and cutaneous cd30+ lymphoma, Am J Dermatopathol 1996; 18:221.

4. LeBoeuf N, McDermott S y Harris N, Case 5-2015, N Engl J Med 2015; 372(7):650-9.

5. Ponce E, Anguita E, Ramírez R y Candel F, htlv-1 infection: an emerging risk. Pathogenesis, epidemiology, diagnosis and associated diseases, Rev Esp Quimioter 2019; 32(6):485-96.

6. Brown RA, Fernández-Pol S y Kim J, Primary cutaneous anaplastic large cell lymphoma, J Cutan Pathol 2017; 44(6):570-7.

7. Kempf W, Kerl K y Mitteldorf C, Cutaneous cd30-positive t-cell lymphoproliferative disorders-clinical and histopathologic features, differential diagnosis, and treatment, Semin Cutan Med Surg 2018; 37(1):24-9.

8. Dawn G, Morrison A, Morton R, Bilsland D y Jackson R, Co-existent primary cutaneous anaplastic large cell lymphoma and lymphomatoid papulosis, Clin Exp Dermatol 2003; 28(6):620-4.

9. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH et al., whoeortc classification for cutaneous lymphomas, Blood 2005; 105:3768-85.

10. Liu V y McKee PH, Cutaneous t-cell lymphoprolipherative disorders: approach for the surgical pathologist. Recent advances and clarification of confused issues, Advance Anat Pathol 2002; 2:79-100.

11. Strutton G, Cutaneous infiltrates-lymphomatous and leukemic. En: Weedon D (ed.), Skin pathology, Londres, Churchill-Livingstone, 2002, pp. 1095-1138.

12. Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S y Kim YH, cd30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cells lymphoma, J Am Acad Dermatol 2003; 49(6):1049-58.

13. Piccinno R, Damiani G, Rossi L y Berti E, Radiotherapy of primary cutaneous anaplastic large cell lymphoma: our experience in 30 cases, Int J Dermatol 2020; 59(4):469-73.

14. Moodley N, Nombona P y Mosam A, Primary cutaneous anaplastic large-cell lymphoma, Dermatopathology J 2019; 6(2):163-9.

15. Pereira DF, Costa BS, Da Paz Scardua EF et al., A primary cutaneous anaplastic large cell lymphoma mimicking labial herpes, Oral Maxillofac Surg 2020; 24:239-42.

16. Bekkenk MW, Geelen FA, Van Voorst Vader PC et al., Primary and secondary cutaneous cd30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment, Blood 2000; 95:3653-61.

17. Kempf W, Pfaltz K, Vermeer MH et al., eortc, iscl, and usclc consensus recommendations for the treatment of primary cutaneous cd30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma, Blood 2011; 118:4024-35.

18. Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S y Kim YH, CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma, J Am Acad Dermatol 2003; 49:1049-58.

19. Marrero-Calvo MD, Rodríguez-Serna M, Castejón-Calvete P y Peláez- Malagón S, Primary cutaneous anaplastic cd30+ large cell lymphoma, Actas Dermosifiliogr 2007; 98:194-7.

20. Duvic M, Tetzlaff M, Clos AL, Gangar P y Talpur R, Phase ii trial of brentuximab vedotin for cd30+ cutaneous t-cell lymphomas and lymphoproliferative disorders, presentada en el 55º encuentro annual de la American Society of Hematology, Nueva Orleans, 7-10 de diciembre de 2013.

21. Zazueta-López RM, Hierro-Orozco S, Achell-Nava L y Jaimes-Hernández V, Uso de biológicos en linfoma cutáneo de células t. Revisión de la bibliografía y comunicación de un caso, Dermatol Rev Mex 2010; 54(4):197-205.

22. Stadler R, Gottle H, Luger T et al., Prospective randomized multicenter clinical trial on the use of interferon α2a plus acit-retin versus interferon α2a plus puva in patients with cutaneus t-cell lymphoma stages i and ii, Blood 1998; 92:3578-81.

23. Duvic M, Talpur R, Ni X, Zhang C et al., Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, saha) for refractory cutaneous tcell lymphoma (ctcl), Blood 2007; 109:31-9.

24. Kempf W, Kerl K y Mitteldorf C, Cutaneous cd30-positive t-cell lymphoproliferative disorders: clinical and histopathologic features, differential diagnosis, and treatment, Semin Cutan Med Surg 2018; 37(1):24-9.